The aim of Annual European Congress of Rheumatology EULAR 2022 is to provide a forum of the highest standard for scientific (both clinical and basic), educational and social exchange between professionals involved in rheumatology, liaising with patient organisations, to achieve progress in the clinical care of people with rheumatic diseases. EULAR is the largest and most significant European meeting within this field.

The paper “A Novel Target for Treatment of Inflammatory Joint Diseases” will be presented by Dr Susanne Lindquist, CSO at Lipum. The work was done together with researcher at Umeå University and SciLifeLab in Uppsala and Stockholm. The abstract will be published on 1 June 2022, according to congress publication embargo policy

For further information, please contact: 

Einar Pontén, CEO
E-post: einar.ponten@lipum.se
Mobile: +46 70 578 34 95
Web:       www.lipum.se

About Lipum
Lipum AB (publ) is a biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in late preclinical stage supported by solid data for the rare disease juvenile idiopathic arthritis and rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission, email: ca@gwkapital.se, phone: +46 8 503 000 50.